Effect of aspirin and simvastatin in schizophrenia

Comparison of aspirin and simvastatin efficacy as adjuvant treatment on negative and positive symptoms and general psychopathology in patient with schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210110049994N1

Enrollment

Registered

2021-02-05

Start date

2021-05-05

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: patients with schizophrenia that were treated by risperidone to whom 650 mg of aspirin (325 mg twice daily) will be added daily. Intervention 2: Intervention group:

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Hospitalized patients with schizophrenia who have been diagnosed for more than 2 years

Exclusion criteria

Exclusion criteria: Patients with schizophrenia with a history of physical illness such as gastrointestinal disorders

Design outcomes

Primary

Measure	Time frame
Comparison of aspirin and simvastatin efficacy as adjuvant treatment on negative and positive symptoms and general psychopathology in patient with schizophrenia. Timepoint: The beginning of the study? 4 and 8 weeks after taking aspirin or simvastatin. Method of measurement: Positive and Negative Symptoms Scale for Schizophrenia.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMatina Pourghasem

University of social welfare and rehabilitation sciences

matinapourghasem@gmail.com+98 21 6691 8929

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026